1Piccart M J,Gore M,Ten Bokkel Huinink W,et al.Docetaxel:an active new drug for treatment of advanced epithelial ovarian cancer.J Natl Cancer Inst,1995,87(9):676-681.
2Markman M,KennedY A,Webster K,et al.Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.J Clin Oncol,2001,19(7):1901-1905.
3Verseh raegen CF,Sittisomwong T,Kudelka AP,et al.Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma.J Clin Oncol,2000,18(14):2733-2739.
4Rose PG,Blessing JA,Ball HG,et al.A phase Ⅱ study of docetaxel in pacitaxel-resistant ovarian and peritoneal carcinoma:a Gynecologic Oncology Group study.Gynecol Oncol,2003,88(2):130-135.
6Ozots RF,Bundy BN,Greet BE,et al.Phase Ⅲ trial for carbop;atin and paelitaxel compared with eisplatin and paclitaxel in patients with optimally resected stage Ⅲ obarian cancer:a Gunecologic Oncology Group study.J Clin Oncol,2003,21(17):3194-3200.
7Latorre A,DeLena M,Catino A,et al.Epithelial ovarian cancer:second and third line chemotherapy (review).Int J Oncol,2002,21(1):179-186.
9Eriguchi M,Osada I,Fujii X,et al.Pilot study for preoperative administration of L.OHP to Patients with advanced scirrhous type gastric cancer.Blomed Pharmacother,1997,51(5):217-220.
1Piccart M J, Gore M, Ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer[J]. J Natl Cancer Inst, 1995, 87(9):676-681.
2Markman M, Kennedy A, Webster K, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum[J]. J Clin Oncol,2001, 19(7):1901-1905.
3Verschraegen C F, Sittisomwong T, Kudelka A P, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma[J]. J Clin Oncol, 2000, 18(14):2733-2739.
4Rose P G, Blessing J A, Ball H G, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2003, 88(2):130-135.
5Berkenblit A, Tung N, Kim Y, et al. Phase I trial of docetaxel, carboplatin, and gemcitabine as first line therapy for patients with high risk epithelial tumors of mullerian origin[J]. Gynecol Oncol,2003, 89(3):486-493.
6Pfisterer J, du Bois A, Wagner U, et al. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group[J]. Gynecol Oncol, 2004, 92(3):949-956.
7Vorobiof D A, Rapoport B L, Chasen M R, et al. Phase II clinical trial of carbopaltin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy [J]. Int J Gynecol Cancer, 2003, 13(3):287-291.
8Dieras V, Guastalla J P, Ferrero J M, et al. A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study[J]. Cancer Chemother Pharmacol, 2004, 53(6): 489-495.
9Neijt J P, Engelholm S A, Tuxen M K, et al. Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer[J]. J Clin Oncol, 2000, 18(17): 3084-3092.
10Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomised trials Advanced Ovarian Cancer Trialists' Group[J]. Br J Cancer,1998, 78(11): 1479-1487.
9Kudoh S, Takeda K, Nakagawa K, et al . Phase Ⅲ study of docetaxel compared with vinorelbine in elderly patients with advanced non - small -cell lung cancer: results of the West Japan Thoracic Oncology Group Trial( WJTOG 9904 ). J Clin Oncol,2006,24 (22) :3657.
10Fossella F, Pereira J R, yon Pawel J, et al. Randomize, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorel- bine plus cisplatin for advanced non - small - cell lung cancer: The TAX326 study group. J clin Oncol,2003,21 (16) :3016.
